3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
31
Lung Neoplasms
14
Neoplasms
10
Thoracic Neoplasms
3
Carcinoma
3
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
NSCLC
2
Meningeal Carcinomatosis
2
Lung Diseases
2
Colorectal Neoplasms
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Brain Neoplasms
2
Adenocarcinoma
2
Solid Tumor, Adult
1
Renal Insufficiency
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Noonan Syndrome
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma, Malignant
1
Lung Cancer Metastatic
1
Lethal Congenital Contracture Syndrome 2
1
Hemangioendothelioma, Epithelioid
1
Head and Neck Neoplasms
1
Interventions
Cisplatin
35
pembrolizumab
29
Radiotherapy
26
Cetuximab
26
Docetaxel
17
Paclitaxel
13
Fluorouracil
13
Cyclophosphamide
12
fludarabine
11
Radiotherapy, Intensity-Modulated
11
Nivolumab
10
Carboplatin
9
atezolizumab
7
Radiation
7
Gemcitabine
7
Erlotinib Hydrochloride
7
Bortezomib
7
fludarabine phosphate
6
Pemetrexed
5
Interleukin-2
5
Radiosurgery
4
Everolimus
4
Drug Therapy
4
Azacitidine
4
olaparib
3
motexafin gadolinium
3
durvalumab
3
cemiplimab
3
Trastuzumab
3
Irinotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Head and Neck Neoplasms
×
osimertinib
×
Clear all
NCT05647122
2026-05-11
EGRET
AstraZeneca
Phase 1
Recruiting
403 enrolled